Komipharm International Co., Ltd.
041960.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$619.61B
Close$
$-1463.56
117.7% downside
Current Fair Value
117.7% downsideOvervalued by 117.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $619.61 Billion |
|---|---|
| Enterprise Value | $639.54 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-100.7 |
| Beta | 0.2 |
| Outstanding Shares | 71,752,191 |
Return
| Return on Equity | -3.60% |
|---|---|
| Return on Assets | -1.86% |
| Return on Invested Capital | 1.47% |
Valuation & Multiples
| P/E Ratio | -240.78 |
|---|---|
| PEG | 201.76 |
| Price to Sales | 11.22 |
| Price to Book Ratio | 8.02 |
| Enterprise Value to Revenue | 12.06 |
| Enterprise Value to EBIT | 517.91 |
| Enterprise Value to Net Income | -248 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.58 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Komipharm International Co., Ltd.
172 employees
CEO: Yang Kyung-hoon Komipharm International Co., Ltd. is a South Korean biopharmaceutical firm specializing in the research, development, and production of veterinary pharmaceuticals and animal vaccines. Their extensive portfolio features vaccines designed ...